Azurity Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.3M
Doctors Paid
10,708
Transactions
22,936
2024 Total
$329,730
Payment Breakdown by Category
Research$8.6M (93.0%)
Food & Beverage$409,495 (4.4%)
Consulting$179,821 (1.9%)
Travel$4,023 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.6M | 104 | 93.0% |
| Food and Beverage | $409,495 | 22,681 | 4.4% |
| Consulting Fee | $179,821 | 101 | 1.9% |
| Honoraria | $27,738 | 10 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,638 | 24 | 0.3% |
| Travel and Lodging | $4,023 | 12 | 0.0% |
| Grant | $3,000 | 1 | 0.0% |
| Education | $11.91 | 3 | 0.0% |
Payments by Type
Research
$8.6M
104 transactions
General
$648,726
22,832 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Active- and Placebo-Controlled, 5-Way Crossover Study to Determine the Abuse Potential of Orally Administered Gabapentin Enacarbil Immediate Release Capsules in Healthy, Nondependent, Recreational Drug Users with Sedative Experience | $5.5M | 0 | 21 |
| A RANDOMIZED, DOUBLE-BLIND, ACTIVE- AND PLACEBO-CONTROLLED, 6 WAY CROSSOVER STUDY TO EVALUATE THE ABUSE POTENTIAL OF ORALLY ADMINISTERED GABAPENTIN ENACARBIL IMMEDIATE RELEASE CAPSULES TAKEN ALONE AND IN COMBINATION WITH OXYCODONE IN HEALTHY, NONDEPENDENT, RECREATIONAL OPIOID USERS | $2.0M | 0 | 10 |
| A Randomized, Single-Dose, Three-Way Crossover, Bioavailability, Bioequivalence and Food Effect Study of Sitagliptin HCl Ready-to-Use 25 mg/mL Oral Solution and Januvia 100 mg Tablets in Healthy Adults | $990,924 | 0 | 7 |
| Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry (VIGILANT) | $91,834 | 0 | 41 |
| Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel Wafer (Carmustine Implant) Used in Usual Medical Practice | $37,617 | 0 | 17 |
| Vancomycin for Primary Sclerosing Cholangitis | $31,677 | 0 | 8 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| John Winkelman, Phd/Md, PHD/MD | Sleep Medicine | Boston, MA | $34,857 | $0 |
| John Mahan, Md, MD | Pediatric Nephrology | Columbus, OH | $17,250 | $0 |
| Scott Weir, Md, MD | Emergency Medicine | Falls Church, VA | $17,063 | $0 |
| Dr. James Wheless, Md, MD | Neurology with Special Qualifications in Child Neurology | Memphis, TN | $15,337 | $0 |
| Ms. Patricia Dean, Arnp, ARNP | Pediatrics | Miami, FL | $12,388 | $0 |
| Siham Accacha, M.d, M.D | Pediatric Endocrinology | Mineola, NY | $11,069 | $0 |
| Dr. Joshua Yang, Md, MD | Pediatric Endocrinology | Orlando, FL | $10,815 | $0 |
| Jerome Lane, Md, MD | Pediatric Nephrology | Chicago, IL | $8,755 | $0 |
| Clifford Chin, M.d, M.D | Pediatric Cardiology | Cincinnati, OH | $6,728 | $0 |
| Dr. Yuk Law, M.d, M.D | Pediatric Cardiology | Seattle, WA | $6,180 | $0 |
| Ashok Vaswani, Md, MD | Endocrinology, Diabetes & Metabolism | Garden City, NY | $5,695 | $0 |
| Michael Perry, Md, MD | Neurodevelopmental Disabilities | Fort Worth, TX | $5,610 | $0 |
| Albert Quan, Md, MD | Pediatric Nephrology | Dallas, TX | $5,115 | $0 |
| Antonio Bianco, M.d, M.D | Internal Medicine | Chicago, IL | $5,028 | $0 |
| Rakhi Kohli, M.d, M.D | Infectious Disease | Boston, MA | $4,867 | $0 |
| William Ondo, M.d, M.D | Neurology | Houston, TX | $4,401 | $0 |
| Aaron Ellenbogen, D.o, D.O | Neurology | Farmington Hills, MI | $4,275 | $0 |
| Dr. Brian Chou, M.d, M.D | Endocrinology, Diabetes & Metabolism | Humble, TX | $4,243 | $0 |
| Bonnie Smeryage, Arnp, ARNP | Pediatrics | Hollywood, FL | $3,780 | $0 |
| Sabry Ayad, M.d, M.D | Anesthesiology | Cleveland, OH | $3,350 | $0 |
| Dr. Joshua Tarkoff, Md, MD | Pediatric Endocrinology | Miami, FL | $3,014 | $0 |
| Raymond Faught, Md, MD | Neurology | Birmingham, AL | $3,000 | $0 |
| Trevor Resnick, Md, MD | Neurology with Special Qualifications in Child Neurology | Miami, FL | $2,523 | $0 |
| Dr. Michael Smith, Md, MD | Neurology | Chicago, IL | $2,379 | $0 |
| Clio Rubinos, M.d, M.D | Neurology | New York, NY | $2,365 | $0 |
Ad
Top Products
- Horizant $7.6M
- HORIZANT $127,070
Associated Products (14)
Payment Categories
- Food & Beverage $409,495
- Consulting $179,821
- Travel & Lodging $4,023
- Research $8.6M
About Azurity Pharmaceuticals, Inc.
Azurity Pharmaceuticals, Inc. has made $9.3M in payments to 10,708 healthcare providers, recorded across 22,936 transactions in the CMS Open Payments database. In 2024, the company paid $329,730. The top product by payment volume is Horizant ($7.6M).
Payments were distributed across 171 medical specialties. The top specialty by payment amount is Internal Medicine ($50,746 to 1,204 doctors).
Payment categories include: Food & Beverage ($409,495), Consulting ($179,821), Research ($8.6M), Travel & Lodging ($4,023).
Azurity Pharmaceuticals, Inc. is associated with 14 products in the CMS Open Payments database, including Horizant, HORIZANT, and FIRVANQ.